Skip to main content
. 2013 Sep 17;8(9):e74893. doi: 10.1371/journal.pone.0074893

Table 1. Subjects in Training and Test Sets.

Variable Training Sets (N=59) Test Set (N=32) P-value
Age at time of analysis, Median (Years, Min, Max) 43 (10-88) 42.0 (12-69) 0.42
SEX, No. (%)
Female 29 (49%) 16 (50%) 1.00
Male 30 (51%) 16 (50%) 1.00
B+CD27+IgM-IgD-, Median (Min, Max) 1.0 (0.0, 22.4) 1.1 (0.0, 6.0) 0.90
IgG, Median (Min, Max) 246.5 (6.0, 898.0) 187.0 (13.0, 597.0) 0.60
IgA, Median (Min, Max) 8.2 (0.0, 535.0) 7.0 (0.0, 95.0) 0.21
IgM, Median (Min, Max) 20.0 (3.0, 205.0) 19.0 (1.0, 247.0) 0.88
Complication, No. (%) 0.66
No 30 (51%) 14 (44%)
Yes 29 (49%) 18 (56%)
Autoimmunity+, No. (%) 0.63
No 41 (69%) 24 (75%)
Yes 18 (31%) 8 (25%)
Splenomegaly+, No. (%) 0.80
No 44 (75%) 25 (78%)
Yes 15 (25%) 7 (22%)
Granuloma+ (Biopsy proven), No. (%) 0.77
No 50 (85%) 26 (81%)
Yes 9 (15%) 6 (19%)
Lymphadenopathy/splenomegaly+, No. (%) 0.43
No 44 (75%) 27 (84%)
Yes 15 (25%) 5 (16%)
Enteropathy, No. (%) 0.10
No 54 (92%) 25 (78%)
Yes 5 (8%) 7 (22%)
+

subjects commonly had more than one of these conditions.